#Ireland #Dublin #Cardiac Imaging #LUMA Vision #VERAFEYE

LUMA Vision's Breakthrough in Cardiac Technology

LUMA Vision Ltd., a trailblazer in cardiac navigation and visualization, has achieved a remarkable milestone with the successful first-in-human application of its revolutionary VERAFEYE™ system. Announced on January 14, 2025, this advancement marks a significant leap forward in cardiac imaging, particularly within the realm of interventional electrophysiology. This innovative platform was recently utilized as part of the LUMINIZE clinical study, setting the stage for transformative changes in how cardiac procedures are performed.

The VERAFEYE™ Advantage

The VERAFEYE™ system is not just another imaging tool; it represents a new era in catheter-based visualization. Unlike traditional methods that deliver only two-dimensional images, the VERAFEYE™ platform provides a stunning four-dimensional view of the heart's intricate anatomy. By employing advanced imaging technology combined with sophisticated maneuverability, this system enhances real-time navigation during complex cardiac procedures. It magnetically tracks third-party catheters, granting clinicians a level of precision and control previously unattainable.

One of the standout features of the VERAFEYE™ catheter is its ability to construct CT-quality reconstructions of atrial chambers in under a minute, something that could dramatically cut down procedure time and improve patient outcomes. This capability is crucial as it allows medical professionals to visualize cardiac structures from all angles, thus providing an interactive experience during procedures. As stated by Professor Gabor Széplaki from the Mater Private Network in Dublin, "The VERAFEYE™ system offers a level of detail that surpasses existing imaging technologies, which allows for better treatment plans for patients with complex heart conditions."

Successful First Procedures

Under Professor Széplaki’s guidance, the first procedures utilizing the VERAFEYE™ platform took place at the Mater Private Network in Dublin. Early outcomes indicated that this innovative system greatly improved procedural efficiency by enhancing the accuracy of imaging and catheter navigation. With the VERAFEYE™ platform, clinicians can now execute intricate treatments with an unmatched level of confidence and information at their fingertips, potentially reducing adverse events and optimizing patient care.

LUMA Vision's CEO, Fionn Lahart, expressed enthusiasm regarding the future applications of this technology: "We are extremely excited about this achievement and what it represents for cardiac care. The potential applications in treating cardiac arrhythmias and other structural heart conditions highlight our team’s dedication to innovating healthcare solutions that meet pressing global clinical needs."

Looking Ahead

As LUMA Vision gears up for market approval of the VERAFEYE™ technology, expectations are high within the medical community. This novel imaging platform not only aims to advance the methods of treating complex cardiac issues but also seeks to enhance overall clinical outcomes for patients around the world. With interactive visuals, real-time imaging, and advanced navigation, the VERAFEYE™ is set to redefine standards in cardiology practices. By empowering clinicians with unprecedented tools, LUMA Vision is aligning itself with future advancements in healthcare technology.

About LUMA Vision

Founded by Fionn Lahart and Christoph Hennersperger, LUMA Vision is dedicated to developing groundbreaking medical device technologies. With headquarters located in Dublin, Ireland, and Munich, Germany, the company is focused on creating solutions that address unmet clinical needs across the globe. The VERAFEYE™ platform is their flagship product designed to significantly enhance cardiac imaging and navigation. For more information, visit www.lumavision.com.